Cargando…

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the tru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408481/ https://www.ncbi.nlm.nih.gov/pubmed/28449657 http://dx.doi.org/10.1186/s12891-017-1520-6

Ejemplares similares

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
por: Ferrari, S., et al.
Publicado: (2015)

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
por: Bone, Henry G., et al.
Publicado: (2013)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
por: Brown, Jacques P, et al.
Publicado: (2013)

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
por: Kendler, D. L., et al.
Publicado: (2018)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension
por: Papapoulos, Socrates, et al.
Publicado: (2012)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
por: Silverman, S., et al.
Publicado: (2013)

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
por: Broadwell, Aaron, et al.
Publicado: (2020)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials
por: Siris, Ethel, et al.
Publicado: (2020)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
por: Tay, Wei Lin, et al.
Publicado: (2022)

Combination and sequential treatments in the management of osteoporosis
por: Papapoulos, Socrates
Publicado: (2012)

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
por: Burckhardt, Peter, et al.
Publicado: (2021)

Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures
por: Ahmed, L. A., et al.
Publicado: (2015)

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
por: Silverman, S. L., et al.
Publicado: (2014)

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group
por: Bilezikian, J.P., et al.
Publicado: (2019)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

Predictors of Imminent Risk of Nonvertebral Fracture in Older, High‐Risk Women: The Framingham Osteoporosis Study
por: Hannan, Marian T, et al.
Publicado: (2019)

ABCDs of the Relative Contributions of Pseudomonas aeruginosa Quorum Sensing Systems to Virulence in Diverse Nonvertebrate Hosts
por: Vasquez-Rifo, Alejandro, et al.
Publicado: (2022)

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
por: Silverman, S. L., et al.
Publicado: (2006)

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
por: Reginster, J. -Y., et al.
Publicado: (2019)

THU445 Complicated Course And Management After Denosumab Discontinuation: A Case Report
por: Arora, Ipsa, et al.
Publicado: (2023)

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
por: Fu, Qiang, et al.
Publicado: (2023)

Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe
por: McCloskey, Eugene, et al.
Publicado: (2022)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ea61mm83sfvoolv38u2d77hu7g